Quantcast
Home > Quotes > APVO

Aptevo Therapeutics Inc. Common Stock (APVO) Quote & Summary Data

APVO 
$2.06
*  
0.06
3%
Get APVO Alerts
*Delayed - data as of Dec. 12, 2018 9:32 ET  -  Find a broker to begin trading APVO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    APVO Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 2 / $ 2.12
1 Year Target
8.5
Today's High / Low
$ 2.06 / $ 2.06
Share Volume
655
50 Day Avg. Daily Volume
90,284
Previous Close
$ 2
52 Week High / Low
$ 6.35 / $ 2
Market Cap
46,736,979
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.24

Intraday Chart

Shares Traded

Share Volume:
655
50 Day Avg. Daily Volume:
90,284

Trading Range

The current last sale of $2.06 is 3.00% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 2.06 $ 6.35
 Low: $ 2.06 $ 2

Company Description (as filed with the SEC)

We are a biotechnology company focused on novel oncology (cancer) and hematology (blood disease) therapeutics to meaningfully improve patients' lives. Our core technology is the ADAPTIR(TM) (modular protein technology) platform. We currently have one revenue-generating product in the area of hematology, as well as various investigational stage product candidates in immuno-oncology and autoimmune and inflammatory diseases. In August 2015, Emergent BioSolutions Inc., or Emergent, announced a plan to separate into two independent publicly traded companies, one a biotechnology company and the other a global specialty life sciences company. To accomplish this separation, Emergent created a new company, Aptevo Therapeutics Inc., or Aptevo, to be the parent company for the development-based biotechnology business focused on novel oncology, hematology, and autoimmune and inflammatory therapeutics.  ... More ...  


Risk Grade

Where does APVO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 2.06
Open Date:
Dec. 12, 2018
Close Price:
$ 2
Close Date:
Dec. 11, 2018

Consensus Recommendation

Analyst Info